📰 Genentech News
Page 235 - Genentech News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Genentech. Real-time updates on events, politics, business and more.
November 22, 2022
/PRNewswire/ -- Byron Allens Allen Media Group (AMG) is proud to announce it has secured numerous major sponsors and advertisers for the inaugural CBS...
November 22, 2022
Watch the latest scientific webinars on SelectScience.
November 22, 2022
/PRNewswire/ -- AbbVie (NYSE: ABBV) will present results from nearly 65 company and partner abstracts across 8 types of cancer during the upcoming American...
November 22, 2022
/PRNewswire/ -- AbbVie (NYSE: ABBV) will present results from nearly 65 company and partner abstracts across 8 types of cancer during the upcoming American...
November 22, 2022
/PRNewswire/ -- Byron Allens Allen Media Group (AMG) is proud to announce it has secured numerous major sponsors and advertisers for the inaugural CBS...
November 21, 2022
Dr. Steven Mamus, Medical Director of Oncology/Hematology, Cancer Center of Sarasota (FL, US), to present how OBD's EpiSwitch CIRT is transforming the way Immune Checkpoint Inhibitor (ICI) therapy
November 21, 2022
Could one of your patients benefit from being enrolled into one of the clinical trials now enrolling patients with breast cancer?
November 18, 2022
One month after a 30-µg booster dose of the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine, neutralizing antibody titers against emerging Omicron sublineages increased 3.2- to 4.8-fold compared to
November 18, 2022
Investegate announcements from BioNTech SE, Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages
November 18, 2022
Teclistamab (Tecvayli) has been approved for relapsed/refractory multiple myeloma patients who have received at least four lines of therapy; typically, such patients have just a few weeks to live.